【适应证】  用于治疗早产儿呼吸窘迫综合征。 

【用法与用量】  短暂停止机械通气后，气管内滴入。 

【注意事项】  本品仅用于气管内给药，外源性表面活性剂可以迅速影响氧合作用和肺的顺应性，因此，使用本品的早产儿要进行临床和实验室评估，根据呼吸情况调整氧气和通气支持系统。在使用本品之前，要纠正酸中毒、低血压、贫血、低血糖和低体温状态。可以改善RDS症状，但不能消除其他早产并发证相关的死亡率和发病率。 

【规格包装】  注射剂。 
【贮藏条件】  2～8℃避光保存，使用前恢复至室温，不要振摇。

【原产地英文商品名】CUROSURF-240MG/3ML VIAL
【原产地英文药品名】PORACTANT ALFA
【原产地英文化合物名称】PORACTANT ALFA
【中文参考商品译名】
注：以下产品不同规格和不同价格，购买时请以电话咨询为准！
·固尔苏-120毫克/1.5毫升瓶
·固尔苏-240毫克/3毫升瓶
【生产厂家英文名】Chiesi Farmaceutici, S.p.A., Parma, Italy

Curosurf® (poractant alfa) is an intratracheal suspension used by healthcare professionals for the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants. The active ingredient of this natural surfactant is the phospholipid fraction obtained from porcine lung.

In adults, but also in term babies, surfactant lines the lungs and stops them from sticking together making normal breathing possible. However premature babies can be born with little or no surfactant, and develop RDS. Nowadays many hospitals give babies born at less than 30 weeks’ gestation age surfactant at birth because it can increase their chances of survival.

Curosurf® is a natural surfactant developed by Chiesi Farmaceutici, S.p.A. , Parma – Italy, in the early 1990s and is now marketed throughout the world in over 40 different countries. It works in the same way as the baby's own surfactant would have done and, therefore, will help the baby to breathe normally until the baby produces his own surfactant.

The introduction of surfactant replacement therapy has contributed to the dramatic decrease of mortality in the premature: in the 1980s (prior to surfactant) a baby born around 28 week gestational age had a 50-70% survival rate whilst nowadays that same baby has a 90% chance of survival. For those born as early as 24 weeks surfactant, along with other improvements in the neonatal care, has resulted in improvements in survival but to a lesser extent.

If a baby is at risk of RDS it is important that a surfactant is given either as a preventative treatment as soon as possible after birth or alternatively, as soon as RDS has been diagnosed, the neonatologist will decide how much is necessary.

Since its first introduction in 1992 it has been estimated that more than 400,000 premature babies have been treated with Curosurf®. Good clinical results together with an excellent safety profile has made surfactant replacement therapy with Curosurf® a well established treatment.